In this regard, several auristatin-based ADCs were generated, of which brentuximab vedotin (anti-CD30 linked to MMAE) was one such ADC, which gained FDA approval in August 2011 to treat CD30-positive Hodgkin’s lymphoma patients [17,222,248,249]. Here, TNFRSF8 is linked to Hodgkins lymphoma.